These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 10989246)

  • 1. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice.
    Zeppetella G; O'Doherty CA; Collins S
    J Pain Symptom Manage; 2000 Aug; 20(2):87-92. PubMed ID: 10989246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and characteristics of breakthrough pain in patients with non-malignant terminal disease admitted to a hospice.
    Zeppetella G; O'Doherty CA; Collins S
    Palliat Med; 2001 May; 15(3):243-6. PubMed ID: 11407195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief.
    Zeppetella G
    J Pain Symptom Manage; 2008 May; 35(5):563-7. PubMed ID: 18258412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain.
    Portenoy RK; Bennett DS; Rauck R; Simon S; Taylor D; Brennan M; Shoemaker S
    J Pain; 2006 Aug; 7(8):583-91. PubMed ID: 16885015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence of episodic pain in cancer: a survey of hospice patients on admission.
    Swanwick M; Haworth M; Lennard RF
    Palliat Med; 2001 Jan; 15(1):9-18. PubMed ID: 11212475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breakthrough pain in opioid-treated patients with neuropathic pain.
    Simon S; Bennett DS; Rauck R; Taylor D; Shoemaker S
    J Opioid Manag; 2006; 2(6):347-52. PubMed ID: 17326597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of breakthrough pain by hospice patients and their caregivers.
    Fine PG; Busch MA
    J Pain Symptom Manage; 1998 Sep; 16(3):179-83. PubMed ID: 9769620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breakthrough pain: definition, prevalence and characteristics.
    Portenoy RK; Hagen NA
    Pain; 1990 Jun; 41(3):273-281. PubMed ID: 1697056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective study of the pathophysiology and clinical characteristics of pain in a palliative medicine population.
    Gutgsell T; Walsh D; Zhukovsky DS; Gonzales F; Lagman R
    Am J Hosp Palliat Care; 2003; 20(2):140-8. PubMed ID: 12693647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breakthrough pain in children with cancer.
    Friedrichsdorf SJ; Finney D; Bergin M; Stevens M; Collins JJ
    J Pain Symptom Manage; 2007 Aug; 34(2):209-16. PubMed ID: 17553659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies.
    Davies A; Zeppetella G; Andersen S; Damkier A; Vejlgaard T; Nauck F; Radbruch L; Sjolund KF; Stenberg M; Buchanan A
    Eur J Pain; 2011 Aug; 15(7):756-63. PubMed ID: 21251860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent cancer pain: clinical importance and an updated cancer pain classification.
    Lasheen W; Walsh D; Sarhill N; Davis M
    Am J Hosp Palliat Care; 2010 May; 27(3):182-6. PubMed ID: 20008824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain.
    Payne R; Coluzzi P; Hart L; Simmonds M; Lyss A; Rauck R; Berris R; Busch MA; Nordbrook E; Loseth DB; Portenoy RK
    J Pain Symptom Manage; 2001 Jul; 22(1):575-83. PubMed ID: 11516599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain.
    Caraceni A; Portenoy RK;
    Pain; 1999 Sep; 82(3):263-274. PubMed ID: 10488677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
    Portenoy RK; Payne R; Coluzzi P; Raschko JW; Lyss A; Busch MA; Frigerio V; Ingham J; Loseth DB; Nordbrock E; Rhiner M
    Pain; 1999 Feb; 79(2-3):303-12. PubMed ID: 10068176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients.
    Farrar JT; Cleary J; Rauck R; Busch M; Nordbrock E
    J Natl Cancer Inst; 1998 Apr; 90(8):611-6. PubMed ID: 9554444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center.
    Hwang SS; Chang VT; Kasimis B
    Pain; 2003 Jan; 101(1-2):55-64. PubMed ID: 12507700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breakthrough pain in cancer patients.
    Zeppetella G
    Clin Oncol (R Coll Radiol); 2011 Aug; 23(6):393-8. PubMed ID: 21227666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and characteristics of breakthrough pain in patients with head and neck cancer: a cross-sectional study.
    Bhatnagar S; Upadhyay S; Mishra S
    J Palliat Med; 2010 Mar; 13(3):291-5. PubMed ID: 20078224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An examination of adherence to pain medication plans in older cancer patients in hospice care.
    Sanders S; Herr KA; Fine PG; Fiala C; Tang X; Forcucci C
    J Pain Symptom Manage; 2013 Jan; 45(1):43-55. PubMed ID: 22841408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.